Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site

    Research output: Contribution to journalReviewResearchpeer-review

  1. The Value of 68Ga-PSMA PET/CT Following Equivocal 18F-NaF PET/CT in Prostate Cancer Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Varicocele Testis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Contemporary Thoughts on the Role of Shockwave Therapy in Peyronie's Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Ejakulationsforstyrrelser

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Marianne Trier Bjerre
  • Maibritt Nørgaard
  • Ole Halfdan Larsen
  • Sarah Østrup Jensen
  • Siri H Strand
  • Peter Østergren
  • Mikkel Fode
  • Jacob Fredsøe
  • Benedicte Parm Ulhøi
  • Martin Mørck Mortensen
  • Jørgen Bjerggaard Jensen
  • Michael Borre
  • Karina D Sørensen
View graph of relations

Novel and minimally-invasive prostate cancer (PCa)-specific biomarkers are needed to improve diagnosis and risk stratification. Here, we investigated the biomarker potential in localized and de novo metastatic PCa (mPCa) of methylated circulating tumor DNA (ctDNA) in plasma. Using the Marmal-aid database and in-house datasets, we identified three top candidates specifically hypermethylated in PCa tissue: DOCK2,HAPLN3, and FBXO30 (specificity/sensitivity: 80%-100%/75-94%). These candidates were further analyzed in plasma samples from 36 healthy controls, 61 benign prostatic hyperplasia (BPH), 102 localized PCa, and 65 de novo mPCa patients using methylation-specific droplet digital PCR. Methylated ctDNA for DOCK2/HAPLN3/FBXO30 was generally not detected in healthy controls, BPH patients, nor in patients with localized PCa despite a positive signal in 98%-100% of matched radical prostatectomy tissue samples. However, ctDNA methylation of DOCK2,HAPLN3, and/or FBXO30 was detected in 61.5% (40/65) of de novo mPCa patients and markedly increased in high- compared to low-volume mPCa (89.3% (25/28) vs. 32.1% (10/31), p < 0.001). Moreover, detection of methylated ctDNA was associated with significantly shorter time to progression to metastatic castration resistant PCa, independent of tumor-volume. These results indicate that methylated ctDNA (DOCK2/HAPLN3/FBXO30) may be potentially useful for identification of hormone-naïve mPCa patients who could benefit from intensified treatment.

Original languageEnglish
JournalCells
Volume9
Issue number6
ISSN2073-4409
DOIs
Publication statusPublished - 31 May 2020

ID: 60069184